Casado J L, Lopez-Velez R, Pintado V, Quereda C, Antela A, Moreno S
Department of Infectious Diseases, Ramon y Cajal Hospital, Madrid, Spain.
Eur J Clin Microbiol Infect Dis. 2001 Mar;20(3):202-5. doi: 10.1007/s100960100457.
The aim of this study was to establish the evolution of visceral leishmaniasis (VL) in 10 consecutive patients coinfected with VL and HIV, taking into account the decline in the incidence of opportunistic infections after the introduction of protease inhibitor therapy. During a median follow-up of 31 months, 7 (70%) of 10 patients relapsed. The incidence of relapse was slightly lower than before institution of protease inhibitor therapy (20 vs. 13 patient-months), with a 31% probability that relapse would not have taken place within 2 years. VL relapses occurred even though increases in the CD4+ cell counts were observed and HIV loads were undetectable, suggesting that successful antiretroviral therapy is not sufficient to control the disease. Relapsing patients also had a lower increase in the CD4+ cell count.
本研究的目的是在考虑到引入蛋白酶抑制剂治疗后机会性感染发病率下降的情况下，确定10例连续的内脏利什曼病（VL）合并HIV感染患者的病情演变。在中位随访31个月期间，10例患者中有7例（70%）复发。复发率略低于蛋白酶抑制剂治疗开始前（20例患者-月对13例患者-月），2年内复发的概率为31%。尽管观察到CD4+细胞计数增加且HIV载量检测不到，但仍发生了VL复发，这表明成功的抗逆转录病毒治疗不足以控制该疾病。复发患者的CD4+细胞计数增加也较低。
